India's Wockhardt launches drug in US market
Facebook Twitter google+ RSS Feed

India's Wockhardt launches drug in US market

Thursday, 21 June 2007, 07:00 Hrs
Printer Print Email Email
Mumbai: Indian pharma major Wockhardt Wednesday announced the launch of its antibiotic tablets Cefprozil in the US after receiving approval from the US Food and Drug Administration (US FDA).

Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections.

"Several of our products have seen a dramatic increase in the market share in the US over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million," Wockhardt chairman Habil Khorakiwala said in a statement.

The Cefprozil tablets, developed in-house, are manufactured at Wockhardt's US FDA certified formulation plant at Waluj in Maharashtra.

The $650 million firm has a market capitalisation of over $1 billion and has major presence in the markets of the US, Britain, Ireland, Germany and France. It employs over 7,000 professionals both in India and abroad.
Source: IANS
Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Philips
Sr. Executive
ISB
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
NIC
Reena Khanna
Founder
Solitaireworld
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset
SPOTLIGHT